Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-07EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Opdualag, a fixed-dose combination of nivolumab and relatlimab, for melanoma, with Bristol-Myers Sq…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies [Phase 1]
Phase 1 clinical trial update showing termination of a study evaluating the combination of ipilimumab and MGN1703 in patients with advanced …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study of VET3-TGI in Patients With Solid Tumors [Phase 1]
Phase 1 clinical trial update for VET3-TGI in patients with solid tumors, currently recruiting across multiple cancer types.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma [Phase 2]
This update describes a Phase 2 clinical trial investigating CD8+ T cell imaging during pre-surgery immunotherapy in people with melanoma. T…
-
CLINICAL_TRIALS other · 2026-04-07Clinical Trial Update: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma [Phase 3]
Pfizer is conducting a Phase 3 trial evaluating Encorafenib, Binimetinib, and Pembrolizumab in advanced or metastatic melanoma. The study is…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) [Phase 1]
Phase 1 study of ADP-A2M4CD8 as monotherapy or in combination with nivolumab or pembrolizumab in HLA-A2+ patients with MAGE-A4-positive tumo…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating oral azacitidine (CC-486) in combination with pembrolizumab (MK-3475) for metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
This clinical trial update reports results from a study examining peripheral T cell determinants of response and resistance to pembrolizumab…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma [Phase 2]
This document describes a Phase 2, single-arm neoadjuvant trial of cemiplimab, fianlimab, and ipilimumab in surgically resectable melanoma. …
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases [EARLY_Phase 1]
A Phase 1 pilot trial evaluating nivolumab plus either ipilimumab or relatlimab for surgically resectable melanoma with brain metastases has…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases [NA]
Clinical trial update on a Gallium-68 labeled PSMA PET/CT tracer being studied to differentiate radiation necrosis from tumor progression in…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants [Phase 1]
Phase 1 study evaluating autologous tumor-infiltrating lymphocytes in pediatric, adolescent, and young adult participants with soft tissue s…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers [Phase 1, Phase 2]
This clinical trial update describes a CD70-targeted CAR-T cell therapy using patients' peripheral blood lymphocytes to treat CD70-expressin…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy [NA]
A clinical trial update comparing single-dose versus multiple-dose radiation in cancer patients with brain metastases who are receiving immu…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Sun Protection and Tanning Awareness in Rural Schools [NA]
A trial evaluating sun protection and tanning awareness in rural schools has completed and results were posted on 2026-04-03. The study was …
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain [Phase 3]
Phase 3 trial comparing longer-duration radiation therapy versus standard radiation therapy for patients with cancer that has spread to the …
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. [Phase 3]
Phase 3 trial evaluating lifileucel plus pembrolizumab versus pembrolizumab alone in untreated advanced melanoma (metastatic/unresectable); …
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma [Phase 1]
Phase 1 clinical trial comparing pharmacokinetics, safety, and immunogenicity of Biocon Biologics' Bmab1700 versus Opdivo (nivolumab) as adj…
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
The ECOG-ACRIN trial assessing biomarker testing practices for common solid cancers in community oncology settings has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma [Phase 1]
Phase 1 trial update reports proof of concept for TBio-4101 in combination with lymphodepleting chemotherapy and IL-2 for relapsed/refractor…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating whether adding tazemetostat to dabrafenib and trametinib improves outcomes in patients with metastatic melan…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease [Phase 1]
Phase 1 study evaluating intravenous and intrathecal nivolumab for leptomeningeal disease in melanoma and non-small cell lung cancer patient…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors [Phase 1]
Phase 1 study assessing safety, tolerability, pharmacokinetics and preliminary efficacy of BAT4706 in patients with advanced solid tumors, i…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients [Phase 2]
Phase 2 trial evaluating a sequence of interleukin-2 with ipilimumab followed by nivolumab for stage III or IV melanoma; currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers [Phase 1]
Phase 1 clinical trial update for PF-08046032 in people with advanced cancers; the study is currently active but not recruiting.